Adverse effect · Survodutide

How common is heart rate increase with Survodutide?

B
Grade B — probable, not settledPhase 2 + 3 · effect size: small · adverse
Short answerProbable, not settled. Human data exist (Phase 2 + 3) and mostly agree, showing a small effect — but too few, too small, or not yet peer-reviewed for a firm answer. Resting heart rate rises a few beats per minute, as with other glucagon-receptor agonists; long-term significance unknown.

What the studies show

Resting heart rate rises a few beats per minute, as with other glucagon-receptor agonists; long-term significance unknown.

Human trials exist and mostly agree, but there are too few of them, they are too small, or one big one is still reading out. Expect the grade to move.

  1. 1

In context

Survodutide is a once-weekly peptide that activates both the GLP-1 and glucagon receptors. In SYNCHRONIZE-1, a 725-person phase 3 trial published in June 2026, it produced 12–13% weight loss at 76 weeks against 5% on placebo, with gastrointestinal symptoms in up to 90% of participants. Its distinctive result is in the liver: a phase 2 trial resolved MASH without worsening fibrosis in 83% of patients at the top dose. It is not approved anywhere.

Survodutide is investigational. Legal status differs by country — see the regulation section or the jurisdiction pages.

Questions

Is Survodutide proven to cause heart rate increase?
Not yet settled. Phase 2 + 3 — LYO grades it B, meaning probable but liable to change as trials read out.
What studies are behind the grade?
Resting heart rate rises a few beats per minute, as with other glucagon-receptor agonists; long-term significance unknown.
Is Survodutide approved for this?
No. Survodutide is investigational; it is not an approved medicine for any indication in the jurisdictions LYO covers.

Other outcomes for Survodutide

Reviewed 3 September 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →